Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Monoclonal Gammopathy of Renal Significance in Finland
NCT06889948Phase 2Recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in monoclonal gammopathy of renal significance (MGRS), sponsored by Helsinki University Hospital. Started Jan 2024; status: recruiting.
02
Drugs
daratumumab
03
Conditions
monoclonal gammopathy of renal significance (MGRS)
Beyond the preview
Go deeper on NCT06889948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889948.